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Objective
Clinical studies of patients with bone sarcomas have been challenged by insufficient 
numbers at individual centres to draw valid conclusions. Our objective was to assess the 
feasibility of conducting a definitive multi-centre randomised controlled trial (RCT) to 
determine whether a five-day regimen of post-operative antibiotics, in comparison to a
24-hour regimen, decreases surgical site infections in patients undergoing endoprosthetic 
reconstruction for lower extremity primary bone tumours. 
Methods
We performed a pilot international multi-centre RCT. We used central randomisation to 
conceal treatment allocation and sham antibiotics to blind participants, surgeons, and data 
collectors. We determined feasibility by measuring patient enrolment, completeness of 
follow-up, and protocol deviations for the antibiotic regimens. 
Results
We screened 96 patients and enrolled 60 participants (44 men and 16 women) across 21 
sites from four countries over 24 months (mean 2.13 participants per site per year, standard 
deviation 2.14). One participant was lost to follow-up and one withdrew consent. Complete 
data were obtained for 98% of eligible patients at two weeks, 83% at six months, and 73% at 
one year (the remainder with partial data or pending queries). In total, 18 participants 
missed at least one dose of antibiotics or placebo post-operatively, but 93% of all post-
operative doses were administered per protocol. 
Conclusions
It is feasible to conduct a definitive multi-centre RCT of post-operative antibiotic regimens in 
patients with bone sarcomas, but further expansion of our collaborative network will be 
critical. We have demonstrated an ability to coordinate in multiple countries, enrol 
participants, maintain protocol adherence, and minimise losses to follow-up.
Cite this article: Bone Joint Res;4:154–162
Article focus
- Clinical studies of patients with bone sarco-
mas have been challenged by insufficient num-
bers at individual centres to draw valid
conclusions.
- The objective of this study was to assess the fea-
sibility of conducting a definitive multi-centre
randomised controlled trial (RCT) to determine
whether a five-day regimen of post-operative
antibiotics in comparison to a 24-hour regimen
decreases surgical site infections (SSIs) in
patients undergoing endoprosthetic reconstruc-
tion for lower extremity primary bone tumours. 
- The authors determined feasibility by measur-
ing patient enrolment, completeness of follow-
up, and protocol deviations for the antibiotic
regimens. 
Key messages
- It is feasible to conduct a definitive multi-
centre RCT of post-operative antibiotic regi-
mens in patients with bone sarcomas.
- The authors demonstrated an ability to
coordinate in multiple countries, enrol partic-
ipants, maintain protocol adherence, and
minimise losses to follow-up.
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- In total, 15% of the participants in this study experi-
enced a SSI.
Strengths and limitations
- There is no precedent for conducting large-scale surgical
trials in this field.
- Pilot studies are often essential before embarking on
large clinical trials because they can demonstrate feasi-
bility, help manage resources, and build a collaborative
network.
- This pilot RCT represents the first ever multi-centre RCT
in sarcoma surgery. 
- Further expansion of the PARITY network will be critical
moving forward
Introduction
The current standard of care for most skeletally mature
patients with lower extremity bone sarcomas is limb sal-
vage surgery, which typically involves tumour resection,
followed by functional limb reconstruction with modular
metallic and polyethylene endoprosthetic implants.1-3
Owing to the complexity and length of these procedures,
as well as the immunocompromised nature of patients
treated with chemotherapy, the risk for post-operative
surgical site infection (SSI) is high.4,5
Post-operative endoprosthetic SSIs often require
staged revision surgery and long-term intravenous (IV)
antibiotic therapy. Even following this management,
repeat infection and ultimate amputation are common.4
Patient function and quality of life can be dramatically
impacted, as can healthcare costs owing to extended hos-
pital stays and multiple re-operations.6,7 The most effec-
tive post-operative regimen of prophylactic antibiotics to
prevent SSIs following endoprosthetic reconstruction for
lower extremity bone tumours is unknown, and current
practice among orthopaedic oncological surgeons is
highly varied.8
Bone sarcomas are rare forms of cancer, and clinical
studies of patients with bone sarcomas have been chal-
lenged by insufficient numbers at individual centres to
draw valid conclusions.9 Sarcomas represent < 1% of all
malignancies, and bone sarcomas affect just four to five
patients per million persons each year.10 High-quality col-
laborative research that can guide clinical practice for
patients with bone sarcomas has lagged behind other
orthopaedic surgery subspecialties, and there have been
no multi-centre randomised controlled trials (RCTs) previ-
ously conducted in the field of orthopaedic oncological
surgery.
Our earlier work has demonstrated high rates of SSI
following the treatment of long bone tumours by surgical
excision and endoprosthetic reconstruction;11 highly var-
ied opinion and practice among orthopaedic oncologists
regarding prophylactic antibiotic regimens;8 an absence
of applicable RCT evidence;9,11 and extensive support
from investigators for a definitive RCT to evaluate a five-
day regimen of post-operative antibiotics in comparison
with a 24-hour regimen of post-operative antibiotics.8,12
In this pilot study, our primary objective was to assess
the feasibility of conducting a definitive multi-centre RCT
to determine whether a five-day regimen of post-
operative antibiotics, in comparison with a 24-hour regi-
men of post-operative antibiotics, decreases the rate of
SSI within one year in patients undergoing endopros-
thetic reconstruction for lower extremity primary bone
tumours. Our secondary objective was to determine the
overall rate of SSI within one year of follow-up in patients
undergoing wide resection and endoprosthetic recon-
struction for lower extremity primary bone tumours.
Patients and Methods
Study design and setting. We performed a pilot interna-
tional multi-centre blinded parallel two-arm RCT. Each
participating site obtained local institutional research eth-
ics board approval and all patients provided informed
consent. This trial was registered at ClinicalTrials.gov
(NCT01479283) and is reported according to the Consol-
idated Standards of Reporting Trials (CONSORT) state-
ment and recommendations for pilot studies.13,14 We
have previously reported our study protocol in further
detail.12
Participants/study subjects. We included patients who
were 12 years of age or older and had lower extremity pri-
mary bone malignancies, benign aggressive tumours, or
soft-tissue sarcomas which had invaded bone and
required surgical excision and endoprosthetic recon-
struction. 
We excluded patients if they had any of the following: 
- Known methicillin-resistant Staphylococcus aureus or
vancomycin-resistant enterococcus skin colonisation; 
- Documented anaphylaxis or angioedema to cefazolin or
penicillin; 
- Prior surgery within the surgical field (excluding a
biopsy); 
- Prior local infection within the surgical field; 
- Known immunologically-deficient conditions of disease
such as HIV (not including recent chemotherapy); 
- Known renal insufficiency with estimated creatinine
clearance (eGRF) of < 54 mL/min; 
- Reconstruction planned to include allograft (bone trans-
plant); 
- Likely problems, according to the judgment of the inves-
tigators, with maintaining follow-up; 
- Unable to provide consent. 
Randomisation. An unblinded pharmacist at each site
randomised participants during surgery to either five
days or 24 hours of post-operative prophylactic cefazolin.
We used a central internet-based computer-generated
randomisation system that concealed allocation. Our ran-
domisation protocol included randomly permuted blocks
of two or four and was stratified by location of tumour
(femur vs tibia) and study centre.
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The participants, surgeons, healthcare providers other
than the pharmacists, data collectors, outcome assessors,
data analysts, and those interpreting the results, were
blinded to treatment allocation. Sites that used pre-mixed
antibiotic bags kept them shrouded as there was a visible
difference between pre-mixed bags and saline.
Interventions. Our protocol instructed that all partici-
pants would receive 2 g of IV cefazolin pre-operatively
within 60 minutes of their procedures, and 2 g of IV
cefazolin every three to four hours intra-operatively. Post-
operatively, participants received either five days or 24
hours of cefazolin according to their randomised treat-
ment assignments:
- Participants in the five-day arm received 2 g of IV cefazo-
lin post-operatively every eight hours for five days. 
- Participants in the 24-hour arm received 2 g of IV cefazo-
lin post-operatively every eight hours for 24 hours, fol-
lowed by sham doses of IV saline (placebo) for an
additional four days.
- Paediatric participants received doses of cefazolin or
sham that were based on 100 mg/kg/day doses, but were
otherwise identical to the adult regimens. 
Surgical excision and endoprosthetic reconstruction
were performed according to the standard practice of the
participating surgeons, which typically involved a wide
extensile exposure, isolation and protection of major
neurovascular structures, and resection of the segment of
bone affected by tumour with a 2 cm to 3 cm bone mar-
gin. Decisions about implant selection, surgical tech-
niques, soft-tissue reconstruction, or post-operative care
other than antibiotic therapy, were left at the discretion of
the treating surgeons, but were recorded in our Case
Report Forms.
Follow-up
We followed participants at two and six weeks; three, six,
and nine months; and one year post-operatively. Trained
research personnel collected all data prospectively
according to standardised procedures, and the Case
Report Forms were transmitted to a central Methods Cen-
ter using a secure electronic data capture system (iData-
Fax, Clinical DataFax Systems Inc., Hamilton, Ontario,
Canada). Other communication with individual sites was
conducted via email, written letters, telephone conversa-
tions, and meetings in person.
Outcome measures. In order to evaluate feasibility, we
measured patient screening and enrolment, complete-
ness of follow-up at each time point, and protocol devia-
tions for the pre-, intra-, and post-operative antibiotic
regimens.
The treating surgeons, study coordinators, and/or their
delegates at each site identified potentially eligible
patients at presentation and classified them as eligible
and included, eligible but missed, or excluded. Com-
pleteness of follow-up was calculated relative to the num-
ber of patients eligible for follow-up at each time point. 
We recorded protocol deviations whenever a pre-,
intra-, or post-operative dose was missed, given incor-
rectly, or supplemented with additional non-study anti-
biotics. When patients were discharged before five days
after surgery, we discontinued their study treatments
early, recorded a protocol deviation for the missed doses,
and no further antibiotics were given.
We pre-specified our criteria for success of the pilot as
enrolment of our pilot sample within two years, 70% or
greater protocol adherence, and 95% or greater com-
pleteness to follow-up. 
To evaluate SSI rates, the participating surgeons diag-
nosed superficial, deep, or organ/space SSI according to
the definition of the Centers for Disease Control and Pre-
vention (CDC), which specifies that at least of one or the
following criteria be met within one year after surgery:12,15
- Purulent drainage from the incision; 
- Organisms isolated from an aseptically-obtained culture
of fluid or tissue from the incision; 
- Incision deliberately opened by surgeon and culture
positive;
- Incision deliberately opened by surgeon or designee
and not cultured, but the patient has at least one of: pain,
tenderness, localised swelling, redness, or heat; 
- Diagnosis of a superficial/deep/organ space incisional
SSI by surgeon. 
Monitoring. Before the start of patient screening and
enrolment at each site, the Methods Center collected and
reviewed the following documents:
- Site Principal Investigator’s current Curriculum Vitae;
- Physician’s Clinical Trial Application;
- Confirmation of ethics approval from the local institu-
tional ethics committee;
- Approved informed consent form(s);
- Site delegation and signature log;
- Qualified Investigator Undertaking Form, if applicable;
- Research Ethics Board Attestation Form, if applicable;
Thereafter, the Methods Center ensured that the Site
Principal Investigator, Research Coordinator, and Phar-
macy Designee had received appropriate study-specific
training, which may have included review of the training
presentation during a teleconference call, independent
review of the training presentation by the site personnel,
or attendance at an Investigator/Coordinator meeting.
During the participant follow-up and clinical data col-
lection phase of the study, the Methods Center remotely
conducted the following ongoing monitoring activities:
- Review quality control reports from the iDataFax system
to identify sites with unacceptable amounts of missing
data or unresolved queries;
- Review enrolment reports to identify sites which have
not been submitting screening data;
- Review the tracking database to identify any inconsisten-
cies between the randomisation system and the submit-
ted Case Report Forms with respect to treatment
allocation;
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- Review site-specific reports on study completion and
loss to follow-up;
- Conduct periodic reviews of the site regulatory binders
for missing and incomplete documentation;
- Review pharmacy logs.
After all subject follow-ups were completed at a clinical
site, the Methods Center conducted the following remote
closeout monitoring activities:
- Ensure that any missing data have been submitted (if
available) and that all remaining data queries have been
resolved;
- Ensure that all required adjudication materials have
been submitted;
- Review the site regulatory file for completion and
request any outstanding documentation;
- Review pharmacy logs;
- Request that the site close out the study with the local
ethics board and submit a copy of the confirmation from
the ethics committee to Chief Executive Officer for the site
regulatory file
An independent Data Safety and Monitoring Board
(DSMB) comprised of three orthopaedic surgeons and a
statistician monitored participant safety. The DSMB
reviewed adverse events and serious adverse events data
on a quarterly basis, met via teleconference at least once
a year, and was governed by a DSMB charter with terms
of reference and functions.
Statistical analysis and study size. Baseline characteristics,
feasibility data, and SSI rates are summarised as means
with standard deviation (SD) or medians with interquar-
tile range (IQR) for continuous variables and counts (%)
for categorical variables. All analyses were conducted
centrally at the Methods Center. Data analysis did not
occur at any of the participating sites.
We enrolled a convenience sample of 60 participants to
evaluate feasibility and we considered our pilot study
completed when the last enrolled participant had
achieved at least three months of follow-up. We esti-
mated that 60 patients would represent approximately
5% to 10% of the definitive RCT sample size (600 to 1200
patients), based on a pairwise comparison with an alpha
of 0.05, a beta of 0.20 (80% power), a relative risk reduc-
tion of 50%,8 and a range of plausible SSI rates.12,16 We
planned a priori to transition directly from our pilot RCT
to a definitive RCT if feasibility was established, with the
pilot event rate used to inform the definitive sample size
estimation.
Results
Recruitment. We screened 96 patients across 21 clinical
sites in Canada, the United States, Australia, and Argen-
tina between November 2012 and October 2014. Of
these, 60 were eligible and included, none were eligible
but missed, and 36 were excluded (Fig. 1). The number of
participants enrolled at each site in this period ranged
from zero (six sites) to 18 (one site), but the initiation of
screening and enrolment was staggered across the par-
ticipating sites because of variability in the time required
to obtain ethics approval and negotiate institutional con-
tracts (Table I). In total, 20 of the sites reported having a
dedicated research nurse or research coordinator avail-
able to assist with the conduct of the trial, and 14
reported prior institutional research experience for clini-
cal trials. Notwithstanding our inclusion and exclusion
criteria, the mean estimated number of endoprosthestic
reconstructions performed at each site per month was 1.8
(SD 1.7).
By October 2014, 11 sites had been open for recruit-
ment for 12 months or more, six sites had been open
for six to 12 months, and four sites had been open for
less than six months. The mean rate of enrolment in the
trial after ‘enrolment-ready’ status was achieved was a
mean of 2.13 (SD 2.4) participants per year across all
sites. 
Screened:
96
Included and randomised:
60
Follow-up complete (12 mths): 27
Follow-up ongoing (<12 mths): 23
Excluded: 36
Missed: 0
Died: 8
Withdrew consent: 1
Lost: 1 
Fig. 1
Flow chart of participants in the trial.
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Baseline characteristics. The baseline characteristics of
the 60 participants are presented in Table II. There were
44 men and 16 women, and their mean age was 41.2
years (SD 23). The most common tumour location was
femur (88%), and the most common tumour type was
osteosarcoma (48%). In total, 47% underwent pre-
operative chemotherapy, and 17% had metastatic disease
at baseline.
Feasibility. As of 24 March 2015, 27 patients completed
12 months of follow-up, 23 patients had completed < 12
months but were still active in the trial, eight patients had
died, one had withdrawn consent the day after surgery,
and one had been lost to follow-up (Fig. 1). Of the
patients that were eligible for each follow-up visit,
complete data were collected for 98% at two weeks,
100% at six weeks, 86% at three months, 83% at six
months, 90% at nine months, and 73% at one year
(Table III). A further 17% of the patients eligible for
follow-up at one year had partially complete data, and
10% had pending queries. 
In total, 58 participants were randomised on the day of
surgery, one was randomised on the first day after sur-
gery, and one was randomised on the day before surgery.
Protocol deviations occurred for the pre-, intra-, or post-
operative antibiotic regimens of 37 participants (61%)
(Table IV). Pre-operatively, three patients did not receive 2 g
of IV cefazolin within 60 minutes of their procedures and
three patients received other antibiotics in addition to
cefazolin according to local institutional protocols, and in
accordance with per-site stratification. Intra-operatively,
seven patients received doses of IV cefazolin other than
2 g every three to four hours owing to dosage adjust-
ments for patient weight, and one patient received other
antibiotics in addition to cefazolin.
Post-operatively, 18 participants missed at least one
dose of cefazolin or placebo: 14 doses were missed
among 11 participants because of pharmacy or nursing
errors; 23 doses were missed among five participants
because they were discharged before five days after sur-
gery; 15 doses were missed in one participant who was
Table I. Participating sites
Hospital Institution Country
Date opened to 
enrolment
Estimated number 
of EPRs per month
Research 
nurse
Research 
assistant
Prior clinical 
trials experience
Mount Sinai Hospital University of Toronto Canada November 2012 2.0 Yes Yes Yes
The Ottawa Hospital University of Ottawa Canada November 2012 1.0 Yes No Yes
Vancouver General 
Hospital
University of 
British Columbia
Canada December 2012 1.5 Yes No Yes
Hôpital Maisonneuve - 
Rosemont
University of
Montreal
Canada December 2012 2.0 Yes Yes No
Juravinski Hospital and
Cancer Centre
McMaster University Canada January 2013 0.3 Yes Yes No
McGill University Health 
Centre
McGill University Canada January 2013 2.0 Yes No Yes
Huntsman Cancer
Institute
University of Utah United States February 2013 5.0 Yes Yes Yes
Vanderbilt Medical 
Center
Vanderbilt University 
School of Medicine
United States March 2013 4.5 Yes No No
Hospital Universitario
Austral
Universidad Austral Argentina May 2013 1.5 Yes Yes No
Beth Israel Deaconess 
Medical Center
Harvard Medical 
School
United States July 2013 0.8 Yes No Yes
Saint-François d’Assisse et 
L’Hotel-Dieu de Quebec
Laval University Canada November 2013 0.6 Yes Yes Yes
Memorial Sloan - Kettering 
Cancer Center
Cornell University United States December 2013 6.0 Yes Yes Yes
Royal Adelaide Hospital University of Adelaide Australia December 2013 1.2 No No Yes
Holden Comprehensive 
Cancer Center
University of Iowa United States October 2013 0.6 Yes No No
Boston Children’s 
Hospital
Harvard Medical 
School
United States February 2014 0.8 Yes No Yes
University of Connecticut 
Health Center
University of 
Connecticut
United States February 2014 0.3 Yes No No
Wexner Medical 
Center
The Ohio State
University
United States April 2014 4.5 Yes No Yes
University of Minnesota 
Medical Center
University of 
Minnesota
United States June 2014 1.0 Yes No Yes
Emory Orthopaedics 
and Spine Center
Emory University United States July 2014 1.7 Yes Yes No
Stanford University 
Hospital and Clinics
Stanford 
University
United States August 2014 0.6 No Yes Yes
The Rothman Institute Thomas Jefferson 
University
United States September 2014 0.8 Yes Yes Yes
EPR, endoprosthetic reconstruction
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started on alternative antibiotics after an intra-operative
complication that led to a staged procedure; and 15
doses were missed in the participant who was ran-
domised before surgery because they died before going
to the operating room. The proportion of post-operative
doses of cefazolin or placebo that were administered per
protocol was 833 out of 900 (93%). Four patients
received other antibiotics in addition to cefazolin post-
operatively within the first five days after surgery. 
SSI
Nine participants (15%) experienced SSI: six were organ/
space, two were deep, and one was superficial. All eight
of the organ/space or deep SSIs were treated with a re-
operation (13%), and the superficial SSI was treated with-
out a re-operation. Three of the SSIs were recorded at the
six-week follow-up visits, two SSIs each were recorded at
the three- and six-months visits, and one SSI each was
recorded at the two-week and one-year visits. 
Table II. Baseline characteristics (n (%) unless otherwise specified).
Characteristic Patients (n = 60)
Mean age (yrs) (SD) 41.2 (23)
Women 16 (27)
Mean weight (kg) (SD) 73.2 (18)
Location of tumour*
Femur 53 (88)
Tibia 7 (12)
Other (acetabulum/ilium) 1 (2)
Type of tumour†
Osteosarcoma 28 (48)
Giant cell tumour of bone 3 (5)
Non-osteogenic sarcoma of bone 5 (8)
Chondrosarcoma 12 (20)
Ewing’s sarcoma 4 (7)
Other‡ 7 (12)
Metastases at baseline
Yes 10 (17)
No 50 (83)
Diabetic 4 (7)
Tobacco use
No 45 (75)
Yes 6 (10)
Yes, quit 9 (15)
Alcohol use
Yes 24 (40)
No 36 (60)
Recreational IV drug use
Yes 0 (0)
No 60 (100)
Undergone other treatment modalities
No 32 (53)
Yes 28 (47)
Pre-operative chemotherapy 28
Pre-operative radiation 0
Other 0
* One patient has both femur and tibia 
† n = 59 (one patient died before surgery, and no tumour characteristics form received)
‡ Epithelioid hemangioma with atypical features, fibrous dysplasia, high grade leiomyosarcoma, lei-
omyosarcoma, lymphoma of bone, pleomorphic sarcoma, synovial chondromatosis 
Table III. Summary of completeness of follow-up
Eligible for follow-up* Completed Partially complete Missed Outstanding
(row %) (row %) (row %) (row %)
2 weeks 57 56 (98) 1 (2) 0 (0) 0 (0)
6 weeks 57 57 (100) 0 (0) 0 (0) 0 (0)
3 months 57 49 (86) 7 (12) 0 (0) 1 (2)
6 months 47 39 (83) 7 (15) 1 (2) 0 (0)
9 months 40 36 (90) 2 (5) 2 (5) 0 (0)
12 months 30 22 (73) 5 (17) 0 (0) 3 (10)
* Number of participants that reached each time point and not died, been lost, or withdrawn
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Discussion
The rarity of bone sarcomas dictates that multi-centre
international collaboration is necessary in order to power
surgical trials adequately in orthopaedic oncology. There
is no precedent for conducting large-scale surgical trials
in this field, however, and this pilot RCT represents the
first ever multi-centre RCT in sarcoma surgery.9 Pilot stud-
ies are often essential before embarking on large clinical
trials because they can demonstrate feasibility, help man-
age resources, and build a collaborative network.14 In this
study, we established the feasibility of conducting a defin-
itive large multi-centre RCT by enrolling of our pilot sam-
ple within two years, and demonstrating high protocol
adherence with minimal losses to follow-up.
Limitations. We required 24 months to enrol 60 patients
across 21 sites from four countries. After accounting for
variability in the timing of start-up at the clinical sites, our
mean enrolment rate was 2.13 participants per site per
year. Our screening data suggest that every eligible
patient was enrolled (no patients were missed), but it is
also possible that some eligible patients were not
screened at all. For example, the most common type of
tumour in our study was osteosarcoma, and the United
States Cancer Statistics Working Group reported nearly
equivalent incidence rates of osteosarcoma in men and
women (5.0 per million vs 5.1 per million, respectively),10
however, we enrolled more men than women in our
study, which raises the possibility of selection bias at the
participating sites. Data from the Surveillance, Epidemiol-
ogy, and End Results database, however, suggested
higher incidence of osteosarcoma in men (5.4 per million
vs 4.0 per million, respectively).17 
Nevertheless, the most likely factor leading to the
imbalance of male versus female participants is our small
sample size and the subsequent likelihood of chance
alone leading to the uneven gender distribution.18 This
factor further highlights the critical importance of con-
ducting large randomised trials as they ensure a balance
of both known and unknown prognostic variables
through the randomisation process.
Our recruitment data suggest that the most critical fac-
tor for the success of our definitive trial will be further
expansion of our collaborative network. At the time of
manuscript submission, the PARITY network consisted of
66 sites: 28 sites are open to enrolment, 30 sites are in var-
ious stages of ethics review or contracts negotiation, and
eight further sites have expressed interest. With the addi-
tion of these sites to the collaborative network, we antici-
pate that the pace of enrolment will continue to accelerate. 
The primary outcome for our definitive trial will be the
rate of SSIs in each arm within one year after surgery, an
endpoint that relies heavily on subjective clinical judg-
ments.19 Although the surgeons in our pilot were
blinded, it is possible our pilot event rate could be biased
towards under reporting, given their involvement in the
cases or that there could have been variability in the way
that the CDC criteria were applied. In order to minimise
bias and variability in the definitive PARITY trial, the defin-
itive trial will implement a blinded Central Adjudication
Committee in order to evaluate all potential SSIs accord-
ing to pre-defined criteria.20 
Feasibility. Sarcoma patients require intense oncological
follow-up to monitor for disease relapse, and we antici-
pated only minimal losses to follow-up in our pilot sam-
ple, but we also implemented several procedures in order
to minimise losses.21 Although only 73% of the patients
eligible for one-year follow-up had complete data avail-
able, we consider that our data support feasibility
because there were only three patients with outstanding
queries at 12 months, and a further 17% of eligible
patients had at least partial data available. Given that
some of the pilot patients are still within their one-year
follow-up period, we expect to resolve most or all of these
outstanding queries and missing data. Only one patient
was lost to follow-up, although one additional patient
withdrew consent on the first day after surgery. With
respect to data quality in relation to participating site
characteristics, we believe that in the pilot phase of this
trial there was a learning curve for all sites, and reporting
of data quality by site at this stage would be premature. 
Table IV. Protocol deviations for pre-, intra-, and post-operative antibiotic
regimens. Data are presented as absolute numbers (%)
Protocol deviation Patients (n = 60)
Pre-operative antibiotics 
Missed dose 3 (5)
Incorrect dose 0 (0)
Received additional antibiotics 3 (5)
Intra-operative antibiotics
Missed at least one dose 0 (0)
Incorrect dose 7 (12)
Received additional antibiotics 1 (2)
Post-operative antibiotics 
Missed at least one dose 18 (30)
Incorrect dose 1 (2)
Received additional antibiotics 4 (7)
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More than half of the participants experienced minor
protocol deviations related to their peri-operative anti-
biotics, but the importance of these deviations to the
validity and feasibility of a definitive trial is doubtful. Ten
participants did not receive the correct regimens of pre-
and intra-operative antibiotics, but it is implausible that
these errors could introduce systematic bias, because
allocation was concealed. Three participants received
additional antibiotics pre-operatively according to local
institutional protocols, but stratification should randomly
distribute these deviations evenly between groups. Trials
with protocol deviations can be considered within a
‘mechanistic-practical’ framework of design and interpre-
tation, whereby mechanistic trials address the impact of
interventions administered under ideal testing circum-
stances, and practical trials address the impact of inter-
ventions administered in ‘real world’ clinical practice.22
Given that most of the protocol deviations in our study
reflected typical clinical practice, and that 93% of all post-
operative doses were administered per protocol, these
protocol deviations are unlikely to compromise the prac-
tical applicability of our results. 
Furthermore, many previous trials in orthopaedic sur-
gery have not adequately reported protocol deviations.23
However, we reported according to the CONSORT state-
ment and recommendations for pilot studies in order to
improve the design and conduct of a subsequent large
definitive trial.14 The doses missed because of pharmacy,
nursing, or randomisation errors will be used as feedback
to guide our future standard operating procedures. 
We coordinated an expert panel of six orthopaedic
oncology surgeons and three infectious disease special-
ists in preparation for this study.8,12,24 Based on our sur-
vey data, expert opinion, and standard of care, we
determined that the most appropriate antibiotic for this
study was cefazolin. Our choice of five days as the long
duration reflects consensus that an even longer duration
would increase the risk for resistant organisms without
providing further antimicrobial effectiveness.25 We stan-
dardised the pre- and intra-operative antibiotic regimens
in order to limit differential co-interventions.
Rates of SSI. In total, 15% of the participants in this study
experienced a SSI. This rate exceeds the weighted mean of
9.5% identified in our systematic review (95% confidence
interval (CI) 8.1 to 11.0), but this finding is not surprising,
because most of the studies in our systematic review were
retrospective case series at risk for selection bias or under
reporting, owing to outcomes assessment bias. Prior stud-
ies have also used widely varying diagnostic criteria, and
only two reported use of the CDC criteria.11 
The minimum follow-up in this pilot was just three
months, but others have reported a median interval from
implantation to infection of 8.5 months.26 Therefore, it is
possible that we could have detected an absolute risk of
infection higher than 15% if all patients were followed up
to one year. To the extent that this is true, a sample size
calculation based on our pilot data might conservatively
over power our definitive PARITY RCT, which would
reduce the likelihood of reporting a spuriously negative
result. Our pilot data support the idea that minimal or no
adjustments to the definitive sample size calculation are
required for losses to follow-up.
In conclusion, it is feasible to conduct a definitive multi-
centre RCT of post-operative antibiotic regimens in patients
with bone sarcomas, but further expansion of our collabor-
ative network will be critical for study completion. We have
demonstrated an ability to coordinate in multiple countries,
enrol participants, maintain protocol adherence, and mini-
mise losses to follow-up. The overall goal of PARITY is to pro-
vide high-quality evidence that can be used in the
development of clinical guidelines. This pilot study has
established a successful network and will support the rigor-
ous design, organisation, and execution of a definitive RCT.
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